Journal article
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Expert review of anticancer therapy, Vol.24(3-4), pp.117-135
04/02/2024
DOI: 10.1080/14737140.2024.2330601
PMID: 38475990
Abstract
IntroductionChemotherapy has been traditionally used as neo-adjuvant therapy in breast cancer for down-staging of locally advanced disease in all sub-types. In the adjuvant setting, genomic assays have shown that a significant proportion of ER positive/HER2 negative patients do not derive benefit from the addition of chemotherapy to adjuvant endocrine therapy. An interest in hormonal treatments as neo-adjuvant therapies in ER positive/HER2 negative cancers has been borne by their documented success in the adjuvant setting. Moreover, cytotoxic chemotherapy is less effective in ER positive/HER2 negative disease compared with other breast cancer subtypes in obtaining pathologic complete responses.Areas coveredNeo-adjuvant therapies for ER positive/HER2 negative breast cancers and associated biomarkers are reviewed, using a Medline survey. A focus of discussion is the prediction of patients that are unlikely to derive extra benefit from chemotherapy and have the highest probabilities of benefiting from hormonal and other targeted therapies.Expert OpinionPredictive biomarkers of response to neo-adjuvant chemotherapy and hormonal therapies are instrumental for selecting ER positive/HER2 negative breast cancer patients for each treatment. Chemotherapy remains the standard of care for many of those patients requiring neo-adjuvant treatment, but other neo-adjuvant therapies are increasingly used.
Details
- Title: Subtitle
- Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
- Creators
- Athina Stravodimou - University Hospital of LausanneIoannis A. Voutsadakis - Sault Area Hospital
- Resource Type
- Journal article
- Publication Details
- Expert review of anticancer therapy, Vol.24(3-4), pp.117-135
- Publisher
- Taylor & Francis
- DOI
- 10.1080/14737140.2024.2330601
- PMID
- 38475990
- ISSN
- 1473-7140
- eISSN
- 1744-8328
- Number of pages
- 19
- Language
- English
- Date published
- 04/02/2024
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984806601902771
Metrics
3 Record Views